Ocular Therapeutix Earnings & Forecasts

Ocular Therapeutix (OCUL) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

四半期利益の驚きの金額

会計四半期	報告日	実質EPS	推定EPS	驚き％
Q2	Aug 3, 2026	$-0.35	$-0.39	10.3 %
Q1	May 5, 2026	$-0.40	$-0.32	-25.0 %
Q4	Feb 5, 2026	$-0.29	$-0.33	12.1 %
Q3	Nov 4, 2025	$-0.38	$-0.36	-5.56 %

Quarterly Revenue (Billions)

四半期売上高の驚きの金額

会計四半期	報告日	実際の収益	推定収益	驚き％
Q2	Aug 3, 2026	$13.48M	$13.10M	2.89 %
Q1	May 5, 2026	$10.79M	$12.71M	-15.1 %
Q4	Feb 5, 2026	$13.25M	$15.73M	-15.7 %
Q3	Nov 4, 2025	$14.54M	$14.09M	3.25 %

Ocular Therapeutix Guidance

Ocular Therapeutix (OCUL) は、11 7, 2023日にfiscal yearの2023に関するガイダンスを直近で発表しました。同社は当期の売上高を$60M - $60Mの範囲と予想しています。

以前のガイダンスと比較して、Ocular Therapeutixは売上高予測を以前の範囲である引き上げから$55M - $60Mに引き上げました。

Ocular Therapeutixは、4から3 6, 2023の間に11 7, 2023ガイダンスの更新を発表しました。During this period, the company raised its outlook 1 time, reflecting management's growing confidence in business performance.

Recent Earnings Results

Metric	Q2 '26	Q1 '26	Q4 '25	Q3 '25
Earnings Per Share (Non-GAAP)
Estimate	$-0.39	$-0.32	$-0.33	$-0.36
Actual	$-0.35	$-0.40	$-0.29	$-0.38
Surprise	+10.3%	-25.0%	+12.1%	-5.56%
Revenue
Estimate	$13.1M	$12.7M	$15.7M	$14.1M
Actual	$13.5M	$10.8M	$13.3M	$14.5M
Surprise	+2.89%	-15.1%	-15.7%	+3.25%

Analyst Estimates — Forward PeriodsSource: Wall Street consensus

Metric	Q3 '26E	Q4 '26E	Q1 '27E	Q2 '27E
Earnings Per Share (Non-GAAP)
Consensus	$-0.35	$-0.37	$-0.38	$-0.37
Revenue
Consensus	$14.3M	$14.1M	—	—

More with Benzinga EdgeGet Access

Earnings & Guidance News

PRO
Ocular Therapeutix Q2 EPS $(0.35) Beats $(0.40) Estimate, Sales $13.475M Beat $13.199M Estimate

Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.40) by 10.26 percent. This is a 10.26 percent increase over losses of $(0.39) per share

Benzinga Newsdesk

Earnings Scheduled For May 5, 2026

Benzinga Insights

PRO
Ocular Therapeutix Q1 EPS $(0.40) Misses $(0.33) Estimate, Sales $10.785M Miss $12.599M Estimate

Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.33) by 21.21 percent. This is a 5.26 percent decrease over losses of $(0.38) per share

Benzinga Newsdesk

Stock Market Today: Dow, Nasdaq, S&P 500 Futures Drop— ZIM Integrated Shipping, Masimo, Toll Brothers In Focus (UPDATED)

(Editor’s note: The future prices of benchmark tracking ETFs, the lede, the economic data, and the headline were updated in the story.) U.S. stock futures declined on Tuesday following Friday’s mixed close at the beginning of the holiday-shortened week, as the markets were closed on Monday for Presidents’ Day.

Rishabh Mishra

PRO
Ocular Therapeutix Q4 EPS $(0.29) Beats $(0.32) Estimate, Sales $13.250M Miss $16.128M Estimate

Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.32) by 9.66 percent. This is unchanged from the same period last year. The company

Benzinga Newsdesk

PRO
Ocular Therapeutix Q3 EPS $(0.38) Misses $(0.37) Estimate, Sales $14.544M Miss $14.627M Estimate

Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.37) by 3.54 percent. This is a 72.73 percent decrease over losses of $(0.22) per share

Benzinga Newsdesk

Ocular Therapeutix Inc